Long-Term Safety of DMTs: What We Know and What We Need to Know

CME
24/01/2025

Listen "Long-Term Safety of DMTs: What We Know and What We Need to Know "

Descargar episodio Ver en sitio original

Episode Synopsis



Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC

Guest: Ahmed Z. Obeidat, MD, PhD



This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

More episodes of the podcast CME

Updates in Major Depressive Disorder with Insomnia 07/11/2025
Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis 03/10/2025
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers 30/09/2025
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers 30/09/2025
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers 30/09/2025
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer 30/09/2025
From Resistance to Response: Evolving Strategies in MDD Management 26/09/2025
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 26/09/2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025 26/09/2025
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 26/09/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA